Dermatologists (Skin Specialists) in Klang, Selangor, Malaysia

If you are looking for a skin specialist in Klang, Selangor (Malaysia); you are at the right place.

Best Skin Specialist Klang

 Skin Specialists or dermatologists are medically qualified doctors who provide a range of skin care services from treating simple skin conditions to diagnosis and management of more complicated skin cases such as Acne, advice on cosmetics, psoriasis, skin cancer, dermatitis, dry skin, rosacea, skin pigmentation etc.

Here is the list of skin specialists in Klang:

Dr Ko Chung Beng
Ko Skin Specialist Centre
12A, Jalan Temoh, Off Jalan Goh Hock Huat, 41400, Klang, Selangor, Malaysia.

Dr A Sivasundram
Sessional Clinic Suite 20, Pantai Hospital Klang ,
Lot 5921, Persiaran Raja Muda Musa, 41200 Klang, Selangor, Malaysia.

Dr Yap Yen Piow
Klinik Pakar Kulit Yap
17A, Lorong Raja Hussein, 41400 Klang, Selangor, Malaysia.


Find your Best Dermatologist in other locations >

Skin Specialist in Kuala Lumpur

Skin Specialists in Petaling Jaya

Skin Specialists in Johor

Skin Specialists in Subang Jaya

Skin Specialist in Puchong

Skin Specialists in Selangor

Skin Specialists in Seremban

Skin Specialists in Penang

Skin Specialists in Malacca

Find your Skin Specialist by Aesthetics and Skincare Treatments

Face
Eyes
Nose
  • Nose Augmentation / Nose Filler > Enquire
  • Non-surgical Nose Job > Enquire
Lip
  • Lip Augmentation / Lip Filler > Enquire
Chin
Neck
Body
Arms
Hair
Women

Comments

Post a Comment

Popular posts from this blog

Semaglutide vs Tirzepatide Muscle Loss: Which Preserves More Lean Mass?

Image
Updated October 2026 Semaglutide and tirzepatide can produce substantial weight loss, but an important question has emerged alongside the popularity of GLP-1-based obesity medicines: How much of the weight lost is fat, and how much is lean mass? The question is more complicated than it first appears. Studies of semaglutide and tirzepatide show that both drugs reduce fat mass and also reduce lean mass during weight loss. However, lean mass is not synonymous with skeletal muscle , and results from separate trials cannot be interpreted as a direct head-to-head comparison of muscle preservation. A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 15,782 participants estimated that lean mass accounted for approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide . However, the authors did not establish that tirzepatide preserves functional skeletal muscle better than semaglutide. The analysis also found that addin...
Read more

GLP-1 Hub 2026: Approved Drugs, Pills vs Injections, Retatrutide & Safety

Image
Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regulated pharmacy. On this page Approval status at a glance Pills vs injections Retatrutide: what is and isn't known Safety, side effects and compounding risks Evidence grades (CEBM) Explore the full GLP-1 & peptide library Using this hub with AI assistants FA...
Read more

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Image
Updated September 2026 GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The most defensible strategy is therefore not to avoid effective obesity treatment, but to improve the quality of weight loss with adequate protein, progressive re...
Read more

GLP-1 Cost and Coverage 2026: Self-Pay, Insurance and Pill Prices

Image
Last reviewed: October 17, 2026. This guide covers prescription GLP-1 and related weight-management medications in the United States. Prices are in US dollars and are subject to change. Manufacturer savings programs have eligibility rules and may expire. The cost of a GLP-1 medication in 2026 can range from under $200 per month for certain oral formulations or introductory self-pay offers to several hundred dollars per month for ongoing treatment. Insurance may lower the cost considerably, but coverage for obesity treatment is not guaranteed—even when a medication is medically appropriate. This guide compares Wegovy (semaglutide), Zepbound (tirzepatide), Foundayo (orforglipron), Ozempic, Mounjaro and other prescription options , with an emphasis on what patients may actually pay. Important: A manufacturer's advertised price is not necessarily your final pharmacy price. Confirm the exact product, prescribed dose, dispensing method, insurance benefit and savings-progra...
Read more

Telehealth Peptide Providers 2026: How to Compare Prescription GLP-1s, Other Peptides, Compounding, Clinical Oversight and Pharmacy Sources

Image
A practical 2026 guide to comparing online peptide and GLP-1 care, with a focus on prescription legitimacy, FDA approval, compounding, clinician oversight, pharmacy sourcing, cost and patient safety. Last updated: October 2, 2026 Scope of this guide: This article primarily examines the U.S. telehealth market because FDA approval and U.S. compounding rules are central to the current peptide landscape. Availability, prescribing rules and product registration differ substantially in other countries. Telehealth has changed how patients access peptide-based medicines. Instead of starting with a traditional clinic visit, patients can often complete an online health assessment, meet a clinician by video or messaging, receive a prescription when medically appropriate, and have medication delivered through a pharmacy. The problem is that the word “peptide” now covers very different categories of products. An FDA-approved prescripti...
Read more

GLP-1 Manual 2026: The Complete Guide to GLP-1 Drugs, Benefits, Risks, Dosing, Muscle Loss & Long-Term Strategy

Image
Updated October 3, 2026 GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care. But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity. This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped. The central idea: GLP-1 therapy should not be judged by the scale alone. The clinically meaningful goal is better health w...
Read more

Ozempic Face: Causes, Evidence, Prevention, Fillers, Biostimulators and Skin Tightening (2026)

Image
Last updated: October 2026 Have you noticed hollow cheeks, deeper smile lines, more visible wrinkles or loose skin after losing weight with Ozempic, Wegovy, Mounjaro or another GLP-1-based medication? These changes are commonly called Ozempic face . The term describes an appearance rather than a formally defined disease. It generally refers to facial volume loss and skin laxity associated with substantial weight loss. Similar changes can occur following bariatric surgery, dietary weight loss and treatment with other weight-management medications. The good news is that several options may improve facial appearance. The important distinction is between preventing avoidable nutritional and muscle losses, replacing lost facial volume and tightening loose skin . These are different problems and do not respond equally to the same treatment. This guide reviews the available evidence, practical prevention strategies, hyaluronic acid fillers, collagen-stimulating biostimulators, e...
Read more

Peptide Therapy in 2026: What the Evidence Says About BPC-157, TB-500, MOTS-c and More

Image
Updated: October 2026 | Editorial team: OneDayMD | Purpose: Evidence and safety education Peptides are increasingly promoted for faster injury recovery, muscle growth, fat loss, better skin, improved sexual function, sleep and “anti-aging.” Some peptide medicines have transformed modern care. Others are experimental compounds with promising laboratory findings but little reliable evidence in people. The word peptide describes a type of molecule. It is not a guarantee of safety, effectiveness, purity or regulatory approval. Insulin and semaglutide are peptides; so are unapproved compounds sold online as “research chemicals.” Their evidence, manufacturing standards and medical uses are not interchangeable. Key takeaways Approved peptide medicines are not the same as research peptides. Approved medicines have been evaluated for specific uses, doses and risks. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon remain investigat...
Read more

SELECT, STEP, SURPASS, SURMOUNT & FLOW: What the Landmark Semaglutide and Tirzepatide Trials Actually Prove (2026)

Image
By Dr. Frank Yap, MD  |  Medically reviewed by One Day MD Review Team  |  Last updated: September 2026 Quick Answer SELECT showed that semaglutide 2.4 mg cuts major cardiovascular events by 20% in people with overweight/obesity and existing heart disease who do not have diabetes. The STEP program (STEP 1–5, STEP 8, and the newer STEP UP trials) established semaglutide's weight-loss profile, with losses ranging from roughly 10% to over 20% of body weight depending on dose, population, and duration. The SURPASS program showed that tirzepatide — a dual GIP/GLP-1 agonist — produces larger HbA1c and weight reductions than semaglutide in type 2 diabetes, and the newly published SURPASS-CVOT (December 2025) confirmed tirzepatide is at least as cardioprotective as dulaglutide. FLOW showed semaglutide cuts major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease, which led the FDA to approve a dedicated kidney-protection in...
Read more

Oral Wegovy vs Foundayo vs Weekly Injections: Which Is Best for Weight Loss in 2026?

Image
Last reviewed: October 17, 2026 The obesity-treatment landscape has changed significantly with the arrival of oral GLP-1 medicines. People who previously had to choose between weekly injections, daily lifestyle changes, and other weight-management treatments now have additional prescription options. Two important oral treatments are Wegovy tablets (semaglutide 25 mg) from Novo Nordisk and Foundayo (orforglipron) from Eli Lilly. Both are taken daily, but they contain different active ingredients and have different administration requirements. Weekly injections remain important alternatives. These include standard-dose Wegovy, higher-dose Wegovy HD in the United States, and tirzepatide sold as Zepbound for weight management in the United States. Which option is best depends on the amount of weight loss needed, convenience, tolerability, other medical conditions, cost, and treatment availability. This guide compares the evidence without assuming that results from separate cl...
Read more